Solving for X: evidence for sex-specific autism biomarkers across multiple transcriptomic studies

Samuel C. Lee^{1,+,*}, Thomas P. Quinn^{1,2,3,+,*}, Jerry Lai⁴, Sek Won Kong⁵, Irva Hertz-Picciotto⁶, Stephen J. Glatt⁷, Tamsyn M. Crowley^{2,3,8}, Svetha Venkatesh¹, and Thin Nguyen¹

¹Centre for Pattern Recognition and Data Analytics (PRaDA), Deakin University, Geelong, 3220, Australia

²Centre for Molecular and Medical Research, Deakin University, Geelong, 3220, Australia

³Bioinformatics Core Research Group, Deakin University, Geelong, 3220, Australia

⁴Deakin eResearch, Deakin University, Geelong, 3220, Australia | Intersect Australia, Sydney, 2000, Australia

⁵Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA | Department of Pediatrics, Harvard Medical School, Boston, MA, USA

⁶Department of Public Health Sciences and UC Davis MIND Institute, School of Medicine, Davis, California

⁷Psychiatric Genetic Epidemiology and Neurobiology Laboratory (PsychGENe Lab) | SUNY Upstate Medical University, Syracuse, NY, USA

⁸Poultry Hub Australia, University of New England, Armidale, New South Wales, 2351, Australia

+ contributed equally, * samleenz@me.com; contacttomquinn@gmail.com

Abstract

Autism spectrum disorder (ASD) is a markedly heterogeneous condition with a varied phenotypic presentation. Its high concordance among siblings, as well as its clear association with specific genetic disorders, both point to a strong genetic etiology. However, the molecular basis of ASD is still poorly understood, although recent studies point to the existence of sex-specific ASD pathophysiologies and biomarkers. Despite this, little is known about how exactly sex influences the gene expression signatures of ASD probands. In an effort to identify sex-dependent biomarkers (and characterise their function), we present an analysis of a single paired-end post-mortem brain RNA-Seq data set and a meta-analysis of six blood-based microarray data sets. Here, we identify several genes with sex-dependent dysregulation, and many more with sex-independent dysregulation. Moreover, through pathway analysis, we find that these sex-independent biomarkers have substantially different biological roles than the sex-dependent biomarkers, and that some of these pathways are ubiquitously dysregulated in both post-mortem brain and blood. We conclude by synthesizing the discovered biomarker profiles with the extant literature, by highlighting the advantage of studying sex-specific dysregulation directly, and by making a call for new transcriptomic data that comprise large female cohorts.

1 Introduction

Autism Spectrum Disorder (ASD) is a markedly heterogeneous condition with a varied phenotypic presentation and a spectrum of disability for those affected. As a neurodevelopmental disorder, the ASD syndrome is characterised by social abnormalities, language abnormalities, and stereotyped behavioural patterns [Bailey et al. \(1996\)](#). The presence of a genetic link in ASD etiology is well-established [Miles \(2011\)](#); [Miyauchi and Voineagu \(2013\)](#), first evidenced by ASD concordance among siblings and by a clear association between ASD and specific genetic disorders (e.g., Fragile X mental retardation) [Bailey et al. \(1996\)](#). This link has prompted a number of transcriptomic studies (e.g., [Hertz-Picciotto et al. \(2006\)](#); [Glatt et al. \(2012\)](#); [Gupta et al. \(2014\)](#)) to identify gene expression signatures (i.e., as a kind of biomarker) that might help elucidate the etiology of ASD and aid in its diagnosis (an important objective since early diagnosis and therapy is shown to improve outcomes in ASD [Elder et al. \(2017\)](#)). However, despite the number of transcriptomic studies performed, the pathophysiology and biomarker profile of ASD are still not known. Rather, these studies have tended to produce inconsistent results, suggesting wide heterogeneity among

both the individual patients and the study populations. Indeed, ASD may not have one signature at all, but instead multiple diverging signatures [Tylee et al. \(2017a\)](#).

Transcriptomic studies of ASD probands typically use cells collected from either post-mortem brains or blood in order to estimate the mRNA abundance for thousands of gene transcripts (by way of microarray technology or massively parallel high-throughput sequencing (RNA-Seq)). Since many expressed transcripts are a precursor to structural or functional proteins, these studies can provide an insight into the functional state of a cell, capturing the common pathway for hereditary predisposition and environmental exposure. Although post-mortem brain studies have an advantage in that they look directly at the tissue of interest, blood-based studies can identify clinically useful biomarkers while also serving as a reliable proxy for gene expression in the brain [Tylee et al. \(2013\)](#) (though a complete understanding of ASD pathophysiology and its biomarker profile will likely require careful consideration of both lines of evidence). To date, more than a dozen studies have measured the transcriptomic profiles of ASD probands (and controls), the results of which have been summarised by two separate meta-analyses [Ch'ng et al. \(2015\)](#); [Ning et al. \(2015\)](#) and one “mega-analysis” [Tylee et al. \(2017a\)](#).

Sex is often called a risk factor for ASD, and it is stated that the risk for a male to have ASD is four to five times higher than that for females [Werling et al. \(2016\)](#); [Christensen et al. \(2016\)](#) (although the magnitude of this difference may be partly due to diagnostic biases [Lai et al. \(2015\)](#)). A similar observation, that the increased male risk is even higher among high-functioning ASD probands [Fombonne \(1999\)](#), likewise suggests that sex-specific mechanisms could influence ASD pathophysiology and its biomarker profile. Further evidence for sex-specific mechanisms is found in recent transcriptomic and functional-imaging studies. For example, Tylee et al., using transformed lymphoblastoid cell lines, found evidence for sex-specific differential regulation of genes and pathways among ASD probands [Tylee et al. \(2017\)](#). Similarly, Trabzuni et al. found sex-specific differences in alternative splicing in adult human brains, including for a well-known ASD risk gene NRXN3 [Trabzuni et al. \(2013\)](#). Functional brain connectivity studies using fMRI imaging have also identified sexual heterogeneity among ASD probands, showing dysregulation in sexually dimorphic brain regions across two large studies [Floris et al. \(2018\)](#); [Lai et al. \(2013\)](#). Moreover, recent work by Mitra et al. found evidence for pleiotropy between common single nucleotide polymorphisms (SNPs) for secondary sex characteristics and ASD risk, as well as sex heterogeneity on the X-chromosome, through a comprehensive SNP “mega-analysis” combining 12 individual data sets from diverse genetic backgrounds [Mitra et al. \(2016\)](#). Taken together, it seems plausible that sex could interact with other genetic and environmental factors to create sex-specific ASD pathophysiologies and biomarker profiles.

As ASD is more common in males, it suggests that females may have some underlying protection whereby a higher risk load is required for them to become afflicted [Robinson et al. \(2013\)](#). One hypothesis posits that ASD itself reflects a shift towards “extreme maleness” such that males are necessarily predisposed [Baron-Cohen \(2002\)](#). In support of this, females with ASD do harbour more (and larger) copy number variants than males with ASDs [Levy et al. \(2011\)](#), and moreover exhibit differential penetrance given the same genetic etiology [Lionel et al. \(2014\)](#) (although Mitra et al. found no evidence for an increased SNP load in females [Mitra et al. \(2016\)](#)). Unfortunately, however, the increased prevalence of ASD in males has led to the exclusion of females from many transcriptomic studies (e.g., [Hu et al. \(2009\)](#); [Sarachana et al. \(2010\)](#); [Alter et al. \(2011\)](#)), making it difficult to understand the male skew in ASD prevalence. Indeed, individual studies are often underpowered to detect subtle sex-specific differences (if they contain female subjects at all). When female subjects are included, sex is typically modelled as a simple covariate rather than an interaction term (i.e. the ASD-sex interaction), meaning that only sex-independent (and not sex-dependent) biomarkers are discovered. When male ASD is contrasted with female ASD, it typically involves loosely comparing simple sex-specific differences (e.g., differential expression present in males but not females, and *vice versa*) in a statistically anticonservative manner. To our knowledge, no study has looked at whether gene expression signatures show a sex-autism interaction across multiple studies and human tissues.

Using a single paired-end post-mortem brain RNA-Seq data set and a meta-analysis of six blood-based microarray data sets, we present an analysis of transcriptomic data that focuses on comparing sex-dependent and sex-independent ASD biomarkers (and the functional profiles thereof) across multiple tissues. By modelling the interaction of sex and ASD directly, we identify biomarkers (as well as functional pathways) that show sex-differences in ASD probands that are different than those in control subjects. Then, for those biomarkers that show no interaction, we pool male and

female probands for a secondary sex-independent analysis. Our results suggest that, despite low power, some genes have FDR-adjusted significant sex-dependent interactions, while even more have significant sex-independent main effects. Subsequent pathway analysis further shows that these sex-independent biomarkers have substantially different biological roles than the sex-dependent biomarkers, and that some of these pathways are ubiquitously dysregulated in both post-mortem brain and blood.

2 Methods

2.1 Data acquisition

2.1.1 RNA-Seq data

We searched for relevant publicly available RNA-Seq data using the Gene Expression Omnibus (GEO) [Barrett and Edgar \(2006\)](#) with the term ("expression profiling by high throughput sequencing"[DataSet Type] AND ("autism spectrum disorder"[MeSH Terms] OR "autistic disorder"[MeSH Terms])) AND "homo sapiens"[Organism] (query made January 2018). We restricted eligible data sets to those sequenced with paired-end and non-poly-A-selected libraries. After excluding any data sets that used cell lines or did not have female cases, only one experiment, GSE107241 [Wright et al. \(2017\)](#), remained. These data comprise a RiboZero Gold paired-end RNA-Seq data set from 52 postmortem dorsolateral prefrontal cortex tissue samples.

Prior to alignment and quantification, raw RNA-Seq reads were trimmed using Trimmomatic (docker image [quay.io/biocontainers/trimmomatic:0.36-4](#)) [Bolger et al. \(2014\)](#) and quality control metrics were recorded (before and after trimming) using FastQC (docker image [biocontainers/fastqc:0.11.5](#)) [Andrews \(2010\)](#). We aligned trimmed reads and quantified expression using Salmon (docker image [combinelab/salmon:0.9.0](#)) [Patro et al. \(2017\)](#) as run in pseudo-quantification mode with a k-mer index of length 31. For the reference, we concatenated a human coding reference (i.e., GRCh38.90.cds) with the corresponding non-coding reference (i.e., GRCh38.90.ncrna).

2.1.2 Microarray data

We collected multiple microarray data sets to perform a meta-analysis of sex-autism interactions and main effects of ASD (i.e., sex-independent effects, where males and females are pooled). We referenced two prior meta-analyses [Ch'ng et al. \(2015\)](#); [Ning et al. \(2015\)](#), and one "mega-analysis" [Tylee et al. \(2017a\)](#), to prepare a list of data sets to study. Of these data sets, we excluded any study that (a) measured transcript expression from brain tissue, (b) had no female cases, (c) used cell lines (i.e., GSE37772 and GSE43076), or (d) treated cells with PPA (i.e., GSE32136). Six data sets remained after exclusion, as described in Table 1.

Data acquired from the Gene Expression Omnibus (GEO) [Barrett and Edgar \(2006\)](#) (i.e., GSE6575 [Gregg et al. \(2008\)](#) and GSE18123 [Kong et al. \(2012\)](#)) were acquired already normalised and were not modified further. The other data sets (i.e., the Glatt et al. Wave I and Wave II data [Glatt et al. \(2012\)](#), the CHARGE study data [Hertz-Picciotto et al. \(2006\)](#), and the Kong et al. 2013 data [Kong et al. \(2013\)](#)) each underwent RMA normalization, quantile normalization, and base-2 logarithm transformation. All subjects with a labelled condition other than typically developed (TD) were assigned to the autism spectrum disorder (ASD) group, except for the two Glatt et al. data sets where "Type-1 errors" were assigned to the TD group. Note that, in crafting this dichotomy, some subjects assigned to the ASD group have delays that fall outside of the "spectrum" *per se*.

2.2 Differential expression analysis of RNA-Seq data

We used DESeq2 (Version 3.6) [Love et al. \(2014\)](#) to test for differential transcript expression within the Salmon-generated counts. We applied a conservative expression filter (i.e., at least 10 estimated counts per-gene in every sample) to the raw count matrix to ensure that the high variability of lowly expressed transcripts did not bias results due to the small group sizes. For each transcript that passed the expression filter, a model was fit using the formula $\sim \text{ASD} * \text{Sex} + \text{Age}$ (where Age is the age of death). Interaction and sex-independent main effects (i.e., of the ASD condition) were then extracted from the model by specifying the relevant contrasts to the DESeq2::results

function. We corrected for multiple testing using the Benjamini-Hochberg procedure [Benjamini and Hochberg \(1995\)](#).

2.3 Meta-analysis of microarray data

Before proceeding with the meta-analysis, we established a set of probes (i.e., for each microarray platform) that represent genes also represented by probes in the other platforms. In other words, we established a final probe set based on the intersection of unique gene symbols present in all microarray platforms under study. Note that we resolved one-to-many mapping ambiguities by excluding any probe that mapped to multiple gene symbols.

For each microarray data set, and for each probe (i.e., of those representing genes found in all data sets), we performed differential expression analysis using *limma* (Version 3.34) [Smyth \(2004\)](#), applying the following steps: (1) fit a model with the formula $\sim \text{ASD} * \text{Sex} + \text{Age}$ where ASD and Sex are each two-level factors (except GSE6575, where the Age covariate is unknown), (2) define contrasts for the sex-autism interaction and for the sex-independent main effects (i.e., of the ASD condition), and (3) measure the differential expression for each contrast using the *eBayes* procedure.

Next, we transformed platform-specific probe p-values to HGNC symbol p-values using *AnnoDbi* (available from Bioconductor [Huber et al. \(2015\)](#)). We resolved many-to-one mapping ambiguities by FDR-adjusting the minimum p-value of all probes for a given gene symbol (i.e., calculating a within-gene FDR correction). We then used Fisher’s method to perform a meta-analysis of the p-values obtained from the differential expression analysis. For K studies, Fisher’s method scores each gene based on (negative two times) the sum of the logarithm of the p-values:

$$\chi_{2K}^2 = -2 \sum_i^K \log p_i \quad (1)$$

This score follows a χ^2 distribution with $2K$ degrees of freedom [Mosteller and Fisher \(1948\)](#). Thus, for each gene, we computed a p-value directly from this score. We corrected for multiple testing using the Benjamini-Hochberg procedure [Benjamini and Hochberg \(1995\)](#).

2.4 Adjustment of latent batch effects

To ensure that latent batch effects did not inflate the discovery of false positives, we performed all analyses above with adjustment for batch effects using *sva* (Version 3.26) [Leek et al. \(2012\)](#); [Leek \(2014\)](#), applying the following steps: (1) estimate the number of surrogate variables while specifying the $\text{ASD} * \text{Sex}$ interaction as the variable of interest and *Age* as an adjustment variable, (2) use the *sva* function (or, in the case of *Salmon*-generated counts, the *svaseq* function) to estimate the surrogate variables, and (3) include the surrogate variables in the differential expression model(s) described above. Generally speaking, using *sva* yielded more conservative results than not using *sva*. All tables and figures show results generated with *sva* except where otherwise noted.

2.5 Pathway analysis and knowledge integration

We performed pathway analysis using GSEA (Version 3.0) [Subramanian et al. \(2005a\)](#) in PreRanked mode with classic enrichment and 1,000 permutations. Enrichment scores were calculated for specific MSigDB (Version 6.1) [Subramanian et al. \(2005b\)](#); [Liberzon et al. \(2011\)](#) gene sets, including the curated KEGG (c2.cp.kegg) [Kanehisa et al. \(2017\)](#), Gene Ontology Biological Process (c5.bp) [The Gene Ontology Consortium \(2017\)](#), Reactome (c2.cp.reactome) [Fabregat et al. \(2018\)](#), and MSigDB Hallmark (h.all) [Liberzon et al. \(2015\)](#) sets.

Based on the nature of the analyses, input rank lists were prepared differently for the RNA-Seq and microarray results. For the RNA-Seq analysis, we ranked transcripts based on the p-value, p , and the magnitude of the fold-change, FC:

$$\text{Rank} = -\log_{10}(p) \times \text{sign}(\log_2(\text{FC})) \quad (2)$$

Then, these transcript-level ranks were converted into gene-level ranks based on the top transcript-level rank. For the microarray meta-analysis, we ranked genes using the χ^2 test statistic (as calculated from Fisher’s method). Note that since this latter metric is agnostic to the direction

of expression changes (i.e., only large χ^2 test statistics suggest dysregulation), we focused here on pathways enriched with a positive score (effectively making this pathway enrichment test one-tailed).

3 Results

3.1 Evidence for sex-dependent autism biomarkers

By modelling the sex-autism interaction directly, we can detect gene expression signatures that have differential dysregulation in male ASD probands when compared with female ASD probands. In other words, we can find sexually dimorphic ASD biomarkers (e.g., a gene up-regulated in male ASD but not in female ASD, or *vice versa*). Despite small study sizes (and disproportionately fewer females), we find some evidence for a sex-autism interaction among biomarkers, especially throughout the microarray meta-analysis data.

From the analysis of the RNA-Seq data derived from post-mortem brain tissue, we find no transcripts with significant (FDR-adjusted p-value < 0.05) sex-dependent dysregulation, although one of these transcripts showed a significant interaction prior to batch correction with *sva*. To illustrate what a sex-autism interaction might look like, Figure 1 shows the per-group expression profiles for the two transcripts with the largest interaction effect (i.e., those with the smallest corrected p-value). Table 2 characterises those transcripts with the most sex-dependent dysregulation.

From the meta-analysis of the blood-based microarray data, we find two genes with significant (FDR-adjusted) sex-dependent dysregulation: *TTF2* and *UTY*. Table 3 characterises those genes with the most sex-dependent dysregulation. Since for a meta-analysis by Fisher’s method, a large departure from the null (i.e., a very small p-value) in only one of several studies could cause the meta-analysis to post a significant result (i.e., even after FDR-adjustment) Tseng et al. (2012), it is useful to inspect visually how each study contributed to the results of the meta-analysis. For this, Figure 2 shows how each study contributed to the meta-analysis findings by plotting the aggregate Fisher score for each gene (of those with large sex-dependent dysregulation) along with the study-wise nominal significance (unadjusted p-value < 0.05). Notably, several of the most significantly dysregulated genes are at least nominally significant in more than one study.

3.2 Evidence for sex-independent autism biomarkers

In situations where a sex-autism interaction is not detectable, we can proceed to measure main condition (i.e., sex-independent) effects by pooling male ASD probands with female ASD probands (and male controls with female controls), without having to model sex as a covariate. Genes with significant sex-independent main effects (i.e., of the ASD condition) have large unidirectional effect sizes in male ASD probands, female ASD probands, or both. Yet, because the interaction is tested first, we can interpret the main condition effects as sex-independent.

From the analysis of the RNA-Seq data derived from post-mortem brain tissue, we find seven transcripts with significant (FDR-adjusted p-value < 0.05) sex-independent differential expression. Of these, only one transcript showed significant up-regulation in ASD (with all others showing down-regulation). Figure 3 shows the expression profile for the two transcripts with the most significant sex-independent main effects (i.e., of the ASD condition). Table 4 characterises those transcripts with significant sex-independent dysregulation. Interestingly, several of the transcripts called differentially expressed by the analysis are annotated as non-coding RNA species.

From the meta-analysis of blood-based microarray data, we find 21 genes with significant (FDR-adjusted) sex-independent dysregulation. Table 5 characterises those genes with the most sex-independent dysregulation. As in Figure 2, Figure 4 shows how each study contributed to the meta-analysis findings by plotting the aggregate Fisher score for each gene (i.e., of those with large sex-independent dysregulation) along with the study-wise nominal significance (unadjusted p-value < 0.05). Again, most genes selected as statistically significant by the meta-analysis are at least nominally significant in more than one study.

3.3 Pathway enrichment of ASD biomarkers

In an effort to summarise the biological relevance of the biomarker profiles generated above, we used the complete ranked lists of the differentially expressed transcripts (and genes) in four separate

gene set enrichment analyses to identify common differentially regulated pathways. Four enrichment profiles were generated using the sex-dependent RNA-Seq (brain) biomarkers, sex-independent RNA-Seq (brain) biomarkers, sex-dependent microarray (blood) biomarkers, and sex-independent microarray (blood) biomarkers.

Figure 5 shows the KEGG pathways enriched by the biomarkers as ranked by the analysis of the RNA-Seq data. For the sex-dependent biomarkers, nine pathways showed significant (FDR-adjusted p-value < 0.15) enrichment. For the sex-independent biomarkers, five pathways showed significant enrichment. Interestingly, all significant enrichment occurred in the same direction.

Figure 6 shows the KEGG pathways enriched by the biomarkers as ranked by the analysis of the microarray data. For the sex-dependent biomarkers, one pathway (i.e., Alanine Aspartate and Glutamate Metabolism) showed significant (FDR-adjusted p-value < 0.30) enrichment. For the sex-independent biomarkers, thirty-six pathways showed significant enrichment. Note that because only positive (i.e., one-tailed) enrichments are considered for these data, an FDR-adjusted p-value < 0.30 is used here (see Methods for more details).

Figure 7 compares the overlap between these significant pathways. For the sex-dependent analyses, no pathways are enriched in both the RNA-Seq and microarray data. However, for the sex-independent analyses, two pathways are enriched in both data. Interestingly, this agreement exists despite differences in the ranked lists, suggesting that ASD biomarker profiles may show some degree of higher-order conservation at the pathway-level that exists not only across multiple studies, but across multiple tissues (as well as multiple transcript quantification assays). Note that we also tested for enrichment among the Gene Ontology Biological Process, Reactome, and MSigDB Hallmarks gene sets, all of which show more examples of overlap between the separate sex-independent analyses (see the Supplementary Information for more details).

4 Discussion

In this report, we present an analysis of several ASD transcriptomic studies, including an analysis of RNA-Seq data derived from post-mortem brain and a meta-analysis of six blood-based microarray data sets. Specifically, we focus on identifying both sex-dependent and sex-independent biomarker profiles for ASD by modelling the sex-autism interaction directly and secondarily measuring main effects of the ASD condition (i.e., sex-independent effects where males and females are pooled). In addition to identifying transcript (and gene) biomarkers, we use gene set enrichment analysis to summarise the observed dysregulation at the pathway level, contrasting sex-dependent pathway enrichment with sex-independent pathway enrichment. In doing so, we find evidence that ASD biomarker profiles may show some degree of higher-order conservation at the pathway level that exists not only across multiple studies, but across multiple tissues (and across multiple transcript quantification assays).

Despite small sample sizes in all studies, we found evidence for the existence of some sex-dependent biomarkers in human tissue. The meta-analysis identified two genes, *TTF2* and *UTY*, with sexually dimorphic expression in the blood. One of these, *TTF2*, plays an important role in normal thyroid development [De Felice and Di Lauro \(2004\)](#). Interestingly, a loss of thyroid hormone homeostasis has been linked to ASD [Berbel et al. \(2014\)](#); [Khan et al. \(2014\)](#). Since it is well-known that thyroid diseases have a sex-specific presentation [Bauer et al. \(2014\)](#), it seems plausible that thyroid abnormalities could contribute to a sexually dimorphic ASD signature. Some thyroid-disrupting environmental chemicals have also been linked to an altered risk for autism [Lyll et al. \(2017\)](#); [Braun et al. \(2014\)](#), including one study showing sexually dimorphic associations [Lyll et al. \(2017\)](#). The other, *UTY*, is a Y-chromosome gene (with considerable homology to an X-chromosome homolog), making any interpretation of its differential dysregulation difficult. Two other genes, *KCNJ8* and *MAP1B*, had FDR-adjusted p-values very close to the pre-defined significance cutoff, warranting follow-up in another study. Although the RNA-Seq analysis did not yield any significant interactions, it is not surprising considering this data set contained only three female ASD probands. Nevertheless, the large (albeit non-significant) effect sizes warrant repeat studies with bigger cohorts and more female ASD probands.

By modelling the sex-autism interaction directly, we are able to follow-up the sex-dependent analysis with a secondary sex-independent analysis for any transcript (or gene) whose expression did not significantly interact with sex. In this scenario, we contrast the pooled male ASD probands and female ASD probands against the pooled male controls and female controls to calculate the main effects (which we can thus interpret as sex-independent biomarkers). Here, over twenty

transcripts and genes exceeded the threshold for FDR-adjusted significance. Interestingly, for the RNA-Seq data, several of the significant biomarkers are not protein-coding genes (highlighting the value of using non-poly-A-selected libraries to quantify both coding and non-coding transcripts). For the microarray meta-analysis, several of the sex-independent biomarkers are associated with key neurodevelopmental processes, including some X-chromosome genes. For example, *MAGED2*, differentially expressed in ASD probands, is located on an X-linked intellectual disability hotspot (i.e., Xp11.2) [Langnaese et al. \(2001\)](#); [Moey et al. \(2016\)](#) (which, if causally relevant, could contribute to the male risk bias).

For both the RNA-Seq analysis and the microarray meta-analysis, we tested the ranked sex-dependent and sex-independent biomarker profiles separately for pathway-level enrichment. We found some pathway enrichment for the sex-dependent profiles, and even more for the sex-independent profiles. Importantly, very few of the enriched pathways were the same for both the interaction and main effects. This suggests that males and females exhibit unique pathway-level signatures that, if causally relevant, might further suggest the existence of both sex-specific and common ASD pathophysiology. Although few KEGG pathways are enriched among the sex-dependent results, there are dozens of significantly enriched sex-dependent pathways across other tested gene sets (see Supplementary Information for more details). Among the sex-independent enriched pathways (for the meta-analysis results), there are a number of pathways for known neurodevelopmental and neurodegenerative diseases, including Huntingtons, Parkinsons, Alzheimers, and amyotrophic lateral sclerosis (ALS), suggesting that at least some of these ASD biomarkers may have functions important to general brain health. Considering that both unique and shared signatures (i.e., at the biomarker-level and pathway-level) exist among ASD probands, it seems plausible that molecular diagnostics could benefit from modelling sex-specific processes directly.

Although we found pathway enrichment to differ considerably between the sex-dependent and sex-independent biomarker profiles, we found that several sex-independent pathways (i.e., based on KEGG and other genes sets) were enriched across both the RNA-Seq and microarray data. Interestingly, this overlap exists despite the fact that analyses were performed on different human tissues (and with different transcript quantification assays). In fact, more than fifty Gene Ontology pathways were enriched among both sets of ranked sex-independent biomarkers (even though no gene products showed significant differential expression in both data). This overlap is consistent with a broad literature supporting common (and perhaps etiologically relevant) gene expression signatures across the widely heterogeneous population of ASD probands. If true, it seems plausible that molecular insights could further benefit from modelling pathway-level dysregulation directly (i.e., in addition to modelling conventional transcriptomic biomarkers).

When we compare our pathway enrichments to the previous ASD “mega-analysis” pathway enrichments [Tylee et al. \(2017b\)](#), we observe several complementary results. First, we found positive enrichment of the MAPK pathway in our sex-dependent RNA-Seq results, agreeing with the male-specific enrichment of Mek targets found in the Tylee et al. study [Tylee et al. \(2017b\)](#). Second, we found an enrichment of the ribosome-related pathway in both of our sex-independent analyses, agreeing with the ribosome-related pathway enrichment identified by the sex-independent “mega-analysis” [Tylee et al. \(2017b\)](#). Third, we found an enrichment of the Toll-like receptor (TLR) signalling pathway in our sex-independent meta-analysis results, agreeing with the TLR 3 and 4 signalling pathway enrichment identified by the sex-independent “mega-analysis” [Tylee et al. \(2017b\)](#). Importantly, these complementary results exist despite considerable differences in statistical methodology and data set inclusion.

Our analysis is not without limitations. First, although we used *sva* to adjust for latent batch effects, it is still possible that any number of remaining factors (or batch effects) could coincide with the diagnostic label (e.g., undocumented co-morbidities or medication use), thereby confounding the discovered biomarker profile. Second, as with any observational study, it is impossible to conclude whether the gene expression signatures (and their biological pathways) are causally related to ASD (or, likewise, the sex-autism interaction), rather than a result of the condition. Third, this analysis is likely under-powered to detect both sex-autism interactions and main effects, owing to the small sample sizes and disproportionately smaller female cohorts. Yet, based on the extant literature (which clearly highlights sex as an ASD risk factor) and the results published here, we believe that modelling the sex-autism interaction should become a mainstay of ASD transcriptomic research. Advantageously, as shown here, interaction modelling is compatible with the most commonly used softwares for batch-effect correction [Leek et al. \(2012\)](#), RNA-Seq analysis [Love et al. \(2014\)](#), and microarray analysis [Smyth \(2004\)](#). Yet, this analytical technique cannot offer

any benefit if transcriptomic studies continue to systematically exclude female subjects (Hu et al. (2009); Sarachana et al. (2010); Alter et al. (2011)). Although there seems to exist a strong skew in the prevalence of male ASD, this very fact underlies the importance of studying female ASD: a complete understanding of the molecular basis of ASD will require the intentional study of both sex-dependent and sex-independent mechanisms, as well as their differences and commonalities.

5 Acknowledgements

SCL and TPQ designed the experiments, performed the analyses, and drafted the manuscript. JL provided statistical expertise and helped revise the manuscript. SWK, IHP, and SJG contributed data and helped revise the manuscript. TMC, SV, and TN supervised the project and helped revise the manuscript. This research was partially supported by the Australian Government through the Australian Research Council’s Linkage Projects funding scheme (LP140100240). SWK is supported by a grant from the National Institute of Health (R01MH107205). IHP is supported by grants from the National Institute of Environmental Health Sciences (1R01ES015359; 2R01ES015359; 1P30ES023513; 3P01ES011269), the National Institute of Health (UG3OD023365), and the United States Environmental Protection Agency (RD83543201).

References

- Alter, M. D., R. Kharkar, K. E. Ramsey, D. W. Craig, R. D. Melmed, T. A. Grebe, R. C. Bay, S. Ober-Reynolds, J. Kirwan, J. J. Jones, J. B. Turner, R. Hen, and D. A. Stephan (2011, February). Autism and increased paternal age related changes in global levels of gene expression regulation. *PloS One* 6(2), e16715.
- Andrews, S. (2010). FastQC a Quality Control Tool for High Throughput Sequence Data [Online].
- Bailey, A., W. Phillips, and M. Rutter (1996, January). Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. *Journal of Child Psychology and Psychiatry, and Allied Disciplines* 37(1), 89–126.
- Baron-Cohen, S. (2002, 6). The extreme male brain theory of autism. *Trends in cognitive sciences* 6(6), 248–254.
- Barrett, T. and R. Edgar (2006). Gene Expression Omnibus (GEO): Microarray data storage, submission, retrieval, and analysis. *Methods in enzymology* 411, 352–369.
- Bauer, M., T. Glenn, M. Pilhatsch, A. Pfennig, and P. C. Whybrow (2014, 2). Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. *Bipolar Disorders* 16(1), 58–71.
- Benjamini, Y. and Y. Hochberg (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* 57(1), 289–300.
- Berbel, P., D. Navarro, and G. C. Román (2014). An evo-devo approach to thyroid hormones in cerebral and cerebellar cortical development: etiological implications for autism. *Frontiers in endocrinology* 5, 146.
- Bolger, A. M., M. Lohse, and B. Usadel (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 30(15).
- Braun, J. M., A. E. Kalkbrenner, A. C. Just, K. Yolton, A. M. Calafat, A. Sjödin, R. Hauser, G. M. Webster, A. Chen, and B. P. Lanphear (2014, 3). Gestational Exposure to Endocrine-Disrupting Chemicals and Reciprocal Social, Repetitive, and Stereotypic Behaviors in 4- and 5-Year-Old Children: The HOME Study. *Environmental Health Perspectives*.
- Ch’ng, C., W. Kwok, S. Rogic, and P. Pavlidis (2015, 10). Meta-Analysis of Gene Expression in Autism Spectrum Disorder. *Autism Research* 8(5), 593–608.

- Christensen, D. L., J. Baio, K. V. N. Braun, D. Bilder, J. Charles, J. N. Constantino, J. Daniels, M. S. Durkin, R. T. Fitzgerald, M. Kurzius-Spencer, L.-C. Lee, S. Pettygrove, C. Robinson, E. Schulz, C. Wells, M. S. Wingate, W. Zahorodny, and M. Yeargin-Allsopp (2016, 4). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. *MMWR. Surveillance Summaries* 65(3), 1–23.
- De Felice, M. and R. Di Lauro (2004, 10). Thyroid Development and Its Disorders: Genetics and Molecular Mechanisms. *Endocrine Reviews* 25(5), 722–746.
- Elder, J. H., C. M. Kreider, S. N. Brasher, and M. Ansell (2017). Clinical impact of early diagnosis of autism on the prognosis and parent-child relationships. *Psychology research and behavior management* 10, 283–292.
- Fabregat, A., S. Jupe, L. Matthews, K. Sidiropoulos, M. Gillespie, P. Garapati, R. Haw, B. Jassal, F. Korninger, B. May, M. Milacic, C. D. Roca, K. Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, G. Viteri, J. Weiser, G. Wu, L. Stein, H. Hermjakob, and P. D’Eustachio (2018, 1). The Reactome Pathway Knowledgebase. *Nucleic Acids Research* 46(D1), D649–D655.
- Floris, D. L., M.-C. Lai, T. Nath, M. P. Milham, and A. Di Martino (2018, 12). Network-specific sex differentiation of intrinsic brain function in males with autism. *Molecular Autism* 9(1), 17.
- Fombonne, E. (1999, 7). The epidemiology of autism: a review. *Psychological medicine* 29(4), 769–86.
- Glatt, S. J., M. T. Tsuang, M. Winn, S. D. Chandler, M. Collins, L. Lopez, M. Weinfeld, C. Carter, N. Schork, K. Pierce, and E. Courchesne (2012, September). Blood-based gene expression signatures of infants and toddlers with autism. *Journal of the American Academy of Child and Adolescent Psychiatry* 51(9), 934–944.e2.
- Gregg, J. P., L. Lit, C. A. Baron, I. Hertz-Picciotto, W. Walker, R. A. Davis, L. A. Croen, S. Ozonoff, R. Hansen, I. N. Pessah, and F. R. Sharp (2008, January). Gene expression changes in children with autism. *Genomics* 91(1), 22–29.
- Gupta, S., S. E. Ellis, F. N. Ashar, A. Moes, J. S. Bader, J. Zhan, A. B. West, and D. E. Arking (2014, December). Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. *Nature Communications* 5, 5748.
- Hertz-Picciotto, I., L. A. Croen, R. Hansen, C. R. Jones, J. van de Water, and I. N. Pessah (2006, July). The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environmental Health Perspectives* 114(7), 1119–1125.
- Hu, V. W., T. Sarachana, K. S. Kim, A. Nguyen, S. Kulkarni, M. E. Steinberg, T. Luu, Y. Lai, and N. H. Lee (2009, April). Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. *Autism Research: Official Journal of the International Society for Autism Research* 2(2), 78–97.
- Huber, W., V. J. Carey, R. Gentleman, S. Anders, M. Carlson, B. S. Carvalho, H. C. Bravo, S. Davis, L. Gatto, T. Girke, R. Gottardo, F. Hahne, K. D. Hansen, R. A. Irizarry, M. Lawrence, M. I. Love, J. MacDonald, V. Obenchain, A. K. Oleś, H. Pagès, A. Reyes, P. Shannon, G. K. Smyth, D. Tenenbaum, L. Waldron, and M. Morgan (2015, 2). Orchestrating high-throughput genomic analysis with Bioconductor. *Nature Methods* 12(2), 115–121.
- Kanehisa, M., M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima (2017). KEGG: New perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Research* 45(D1), D353–D361.
- Khan, A., J. W. Harney, A. M. Zavacki, and E. M. Sajdel-Sulkowska (2014, 4). Disrupted brain thyroid hormone homeostasis and altered thyroid hormone-dependent brain gene expression in autism spectrum disorders. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society* 65(2), 257–72.

- Kong, S. W., C. D. Collins, Y. Shimizu-Motohashi, I. A. Holm, M. G. Campbell, I.-H. Lee, S. J. Brewster, E. Hanson, H. K. Harris, K. R. Lowe, A. Saada, A. Mora, K. Madison, R. Hundley, J. Egan, J. McCarthy, A. Eran, M. Galdzicki, L. Rappaport, L. M. Kunkel, and I. S. Kohane (2012). Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. *PLoS One* 7(12), e49475.
- Kong, S. W., Y. Shimizu-Motohashi, M. G. Campbell, I. H. Lee, C. D. Collins, S. J. Brewster, I. A. Holm, L. Rappaport, I. S. Kohane, and L. M. Kunkel (2013, May). Peripheral blood gene expression signature differentiates children with autism from unaffected siblings. *Neurogenetics* 14(2), 143–152.
- Lai, M.-C., M. V. Lombardo, B. Auyeung, B. Chakrabarti, and S. Baron-Cohen (2015, 1). Sex/gender differences and autism: setting the scene for future research. *Journal of the American Academy of Child and Adolescent Psychiatry* 54(1), 11–24.
- Lai, M.-C., M. V. Lombardo, J. Suckling, A. N. V. Ruigrok, B. Chakrabarti, C. Ecker, S. C. L. Deoni, M. C. Craig, D. G. M. Murphy, E. T. Bullmore, and S. Baron-Cohen (2013, 9). Biological sex affects the neurobiology of autism. *Brain* 136(9), 2799–2815.
- Langnaese, K., D. Kloos, M. Wehnert, B. Seidel, and P. Wieacker (2001). Expression pattern and further characterization of human MAGED2 and identification of rodent orthologues. *Cytogenetic and Genome Research* 94(3-4), 233–240.
- Leek, J. T. (2014, 12). svaseq: removing batch effects and other unwanted noise from sequencing data. *Nucleic Acids Research* 42(21), e161–e161.
- Leek, J. T., W. E. Johnson, H. S. Parker, A. E. Jaffe, and J. D. Storey (2012, March). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28(6), 882–883.
- Levy, D., M. Ronemus, B. Yamrom, Y.-h. Lee, A. Leotta, J. Kendall, S. Marks, B. Lakshmi, D. Pai, K. Ye, A. Buja, A. Krieger, S. Yoon, J. Troge, L. Rodgers, I. Iossifov, and M. Wigler (2011, June). Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum Disorders. *Neuron* 70(5), 886–897.
- Lex, A., N. Gehlenborg, H. Strobel, R. Vuilleumot, and H. Pfister (2014, 12). UpSet: Visualization of Intersecting Sets. *IEEE Transactions on Visualization and Computer Graphics* 20(12), 1983–1992.
- Liberzon, A., C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. Mesirov, and P. Tamayo (2015, 12). The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Systems* 1(6), 417–425.
- Liberzon, A., A. Subramanian, R. Pinchback, H. Thorvaldsdóttir, P. Tamayo, and J. P. Mesirov (2011, 6). Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27(12), 1739–1740.
- Lionel, A. C., K. Tammimies, A. K. Vaags, J. A. Rosenfeld, J. W. Ahn, D. Merico, A. Noor, C. K. Runke, V. K. Pillalamarri, M. T. Carter, M. J. Gazzellone, B. Thiruvahindrapuram, C. Fagerberg, L. W. Laulund, G. Pellicchia, S. Lamoureux, C. Deshpande, J. Clayton-Smith, A. C. White, S. Leather, J. Trounce, H. Melanie Bedford, E. Hatchwell, P. S. Eis, R. K. C. Yuen, S. Walker, M. Uddin, M. T. Geraghty, S. M. Nikkel, E. M. Tomiak, B. A. Fernandez, N. Soreni, J. Crosbie, P. D. Arnold, R. J. Schachar, W. Roberts, A. D. Paterson, J. So, P. Szatmari, C. Chrysler, M. Woodbury-Smith, R. Brian Lowry, L. Zwaigenbaum, D. Mandym, J. Wei, J. R. Macdonald, J. L. Howe, T. Nalpathamkalam, Z. Wang, D. Tolson, D. S. Cobb, T. M. Wilks, M. J. Sorensen, P. I. Bader, Y. An, B.-L. Wu, S. A. Musumeci, C. Romano, D. Postorivo, A. M. Nardone, M. D. Monica, G. Scarano, L. Zoccante, F. Novara, O. Zuffardi, R. Ciccone, V. Antona, M. Carella, L. Zelante, P. Cavalli, C. Poggiani, U. Cavallari, B. Argiropoulos, J. Chernos, C. Brasch-Andersen, M. Speevak, M. Fichera, C. M. Ogilvie, Y. Shen, J. C. Hodge, M. E. Talkowski, D. J. Stavropoulos, C. R. Marshall, and S. W. Scherer (2014, May). Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. *Human Molecular Genetics* 23(10), 2752–2768.
- Love, M. I., W. Huber, and S. Anders (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 15(12), 550.

- Lyall, K., L. A. Croen, A. Sjödin, C. K. Yoshida, O. Zerbo, M. Kharrazi, and G. C. Windham (2017). Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability. *Environmental health perspectives* 125(3), 474–480.
- Lyall, K., L. A. Croen, L. A. Weiss, M. Kharrazi, M. Traglia, G. N. Delorenze, and G. C. Windham (2017, 8). Prenatal Serum Concentrations of Brominated Flame Retardants and Autism Spectrum Disorder and Intellectual Disability in the Early Markers of Autism Study: A Population-Based Case–Control Study in California. *Environmental Health Perspectives* 125(8), 087023.
- Miles, J. H. (2011, 4). Autism spectrum disorders—a genetics review. *Genetics in medicine : official journal of the American College of Medical Genetics* 13(4), 278–294.
- Mitra, I., K. Tsang, C. Ladd-Acosta, L. A. Croen, K. A. Aldinger, R. L. Hendren, M. Traglia, A. Lavillaureix, N. Zaitlen, M. C. Oldham, P. Levitt, S. Nelson, D. G. Amaral, I. Hetz-Picciotto, M. D. Fallin, and L. A. Weiss (2016, 11). Pleiotropic Mechanisms Indicated for Sex Differences in Autism. *PLOS Genetics* 12(11), e1006425.
- Miyauchi, S. and I. Voineagu (2013). Autism susceptibility genes and the transcriptional landscape of the human brain. *International review of neurobiology* 113, 303–318.
- Moey, C., S. J. Hinze, L. Brueton, J. Morton, D. J. McMullan, B. Kamien, C. P. Barnett, N. Brunetti-Pierri, J. Nicholl, J. Gecz, and C. Shoubridge (2016, 3). Xp11.2 microduplications including IQSEC2, TSPYL2 and KDM5C genes in patients with neurodevelopmental disorders. *European Journal of Human Genetics* 24(3), 373–380.
- Mosteller, F. and R. A. Fisher (1948). Questions and Answers. *The American Statistician* 2(5), 30–31.
- Ning, L. F., Y. Q. Yu, E. T. GuoJi, C. G. Kou, Y. H. Wu, J. P. Shi, L. Z. Ai, and Q. Yu (2015, March). Meta-analysis of differentially expressed genes in autism based on gene expression data. *Genetics and molecular research: GMR* 14(1), 2146–2155.
- Patro, R., G. Duggal, M. I. Love, R. A. Irizarry, and C. Kingsford (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nature Methods* 14(4), 417–419.
- Robinson, E. B., P. Lichtenstein, H. Anckarsäter, F. Happé, and A. Ronald (2013, 3). Examining and interpreting the female protective effect against autistic behavior. *Proceedings of the National Academy of Sciences of the United States of America* 110(13), 5258–62.
- Sarachana, T., R. Zhou, G. Chen, H. K. Manji, and V. W. Hu (2010, April). Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. *Genome Medicine* 2(4), 23.
- Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Statistical Applications in Genetics and Molecular Biology* 3, Article3.
- Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov (2005a, October). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences* 102(43), 15545–15550.
- Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov (2005b). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences* 102(43), 15545–15550.
- The Gene Ontology Consortium (2017, 1). Expansion of the Gene Ontology knowledgebase and resources. *Nucleic Acids Research* 45(D1), D331–D338.
- Trabzuni, D., A. Ramasamy, S. Imran, R. Walker, C. Smith, M. E. Weale, J. Hardy, M. Ryten, and N. A. B. E. Consortium (2013, 11). Widespread sex differences in gene expression and splicing in the adult human brain. *Nature Communications* 4, 2771.

- Tseng, G. C., D. Ghosh, and E. Feingold (2012, May). Comprehensive literature review and statistical considerations for microarray meta-analysis. *Nucleic Acids Research* 40(9), 3785–3799.
- Tylee, D. S., A. J. Espinoza, J. L. Hess, M. A. Tahir, S. Y. McCoy, J. K. Rim, T. Dhimal, O. S. Cohen, and S. J. Glatt (2017, 3). RNA sequencing of transformed lymphoblastoid cells from siblings discordant for autism spectrum disorders reveals transcriptomic and functional alterations: Evidence for sex-specific effects. *Autism Research* 10(3), 439–455.
- Tylee, D. S., J. L. Hess, T. P. Quinn, R. Barve, H. Huang, Y. Zhang-James, J. Chang, B. S. Stamova, F. R. Sharp, I. Hertz-Picciotto, S. V. Faraone, S. W. Kong, and S. J. Glatt (2017a, April). Blood transcriptomic comparison of individuals with and without autism spectrum disorder: A combined-samples mega-analysis. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics* 174(3), 181–201.
- Tylee, D. S., J. L. Hess, T. P. Quinn, R. Barve, H. Huang, Y. Zhang-James, J. Chang, B. S. Stamova, F. R. Sharp, I. Hertz-Picciotto, S. V. Faraone, S. W. Kong, and S. J. Glatt (2017b, 4). Blood transcriptomic comparison of individuals with and without autism spectrum disorder: A combined-samples mega-analysis. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 174(3), 181–201.
- Tylee, D. S., D. M. Kawaguchi, and S. J. Glatt (2013, October). On the outside, looking in: a review and evaluation of the comparability of blood and brain "-omes". *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics* 162B(7), 595–603.
- Werling, D. M., N. N. Parikshak, and D. H. Geschwind (2016, 2). Gene expression in human brain implicates sexually dimorphic pathways in autism spectrum disorders. *Nature Communications* 7, 10717.
- Wright, C., J. H. Shin, A. Rajpurohit, A. Deep-Soboslay, L. Collado-Torres, N. J. Brandon, T. M. Hyde, J. E. Kleinman, A. E. Jaffe, A. J. Cross, and D. R. Weinberger (2017, 5). Altered expression of histamine signaling genes in autism spectrum disorder. *Translational psychiatry* 7(5), e1126.

List of Figures

- 1 These violin plots show the base-2 logarithm-transformed expression for the two transcripts with the largest interaction effect from the RNA-Seq data (i.e., those with the smallest corrected p-value). The solid lines show sex-specific mean expression differences. The dashed line shows the sex-independent (i.e., pooled) mean expression difference. 14
- 2 This figure shows the genes with the most significant sex-dependent dysregulation (i.e., a sex-autism interaction) according to the meta-analysis of the microarray data. Above, the bar plot shows the χ^2 score for each gene as calculated using Fisher's method (where the dark bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows whether a gene showed a nominally significant sex-dependent dysregulation at an unadjusted p-value < 0.05 for a given study. Note that most genes selected for by the meta-analysis show at least nominal significance across multiple studies. 15
- 3 These violin plots show base-2 logarithm-transformed expression for the two most significant main effects (i.e., of the ASD condition) from the RNA-Seq data. The solid lines show sex-specific mean expression differences. The dashed line shows the sex-independent (i.e., pooled) mean expression difference. 16
- 4 This figure shows the genes with the most significant sex-independent main effects (i.e., of the ASD condition) according to the meta-analysis of the microarray data. Above, the bar plot shows the χ^2 score for each gene as calculated using Fisher's method (where the dark bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows whether a gene showed a nominally significant sex-independent main effect at an unadjusted p-value < 0.05 for a given study. Note that most genes selected for by the meta-analysis show at least nominal significance across multiple studies. 17
- 5 This dot plot shows results from a GSEA of the RNA-Seq data against the MSigDB KEGG pathways. For the two sets of results (i.e., the sex-autism interaction and the main effect), a KEGG pathway (y-axis) has a circle (or triangle) if it is enriched (or depleted). The size of the points indicates the absolute normalised enrichment score. The colour indicates the FDR. Note that only points with an FDR < 0.3 are plotted (see Methods). 18
- 6 This dot plot shows results from a GSEA of the meta-analysis data against the MSigDB KEGG pathways. For the two sets of results (i.e., the sex-autism interaction and the main effect), a KEGG pathway (y-axis) has a circle if it is enriched. The size of the points indicates the absolute normalised enrichment score. The colour indicates the FDR. Note that only points with an FDR < 0.3 are plotted (see Methods). 19
- 7 This UpSet plot Lex et al. (2014) shows set intersections (and their sizes) from a GSEA of four results against the MSigDB KEGG pathways. Set identity is indicated by the joined lines. Set size is indicated by the top bar chart. The bar chart on the left shows the total set size for each individual GSEA run. Results are filtered using a liberal FDR threshold of FDR < 0.15 for the RNA-Seq data and FDR < 0.3 for the meta-analysis data (see Methods). 20

Figure 1: These violin plots show the base-2 logarithm-transformed expression for the two transcripts with the largest interaction effect from the RNA-Seq data (i.e., those with the smallest corrected p-value). The solid lines show sex-specific mean expression differences. The dashed line shows the sex-independent (i.e., pooled) mean expression difference.

Figure 2: This figure shows the genes with the most significant sex-dependent dysregulation (i.e., a sex-autism interaction) according to the meta-analysis of the microarray data. Above, the bar plot shows the χ^2 score for each gene as calculated using Fisher's method (where the dark bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows whether a gene showed a nominally significant sex-dependent dysregulation at an unadjusted p-value < 0.05 for a given study. Note that most genes selected for by the meta-analysis show at least nominal significance across multiple studies.

Figure 3: These violin plots show base-2 logarithm-transformed expression for the two most significant main effects (i.e., of the ASD condition) from the RNA-Seq data. The solid lines show sex-specific mean expression differences. The dashed line shows the sex-independent (i.e., pooled) mean expression difference.

Figure 4: This figure shows the genes with the most significant sex-independent main effects (i.e., of the ASD condition) according to the meta-analysis of the microarray data. Above, the bar plot shows the χ^2 score for each gene as calculated using Fisher's method (where the dark bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows whether a gene showed a nominally significant sex-independent main effect at an unadjusted p-value < 0.05 for a given study. Note that most genes selected for by the meta-analysis show at least nominal significance across multiple studies.

Figure 5: This dot plot shows results from a GSEA of the RNA-Seq data against the MSigDB KEGG pathways. For the two sets of results (i.e., the sex-autism interaction and the main effect), a KEGG pathway (y-axis) has a circle (or triangle) if it is enriched (or depleted). The size of the points indicates the absolute normalised enrichment score. The colour indicates the FDR. Note that only points with an FDR < 0.3 are plotted (see Methods).

Figure 6: This dot plot shows results from a GSEA of the meta-analysis data against the MSigDB KEGG pathways. For the two sets of results (i.e., the sex-autism interaction and the main effect), a KEGG pathway (y-axis) has a circle if it is enriched. The size of the points indicates the absolute normalised enrichment score. The colour indicates the FDR. Note that only points with an FDR < 0.3 are plotted (see Methods).

Figure 7: This UpSet plot [Lex et al. \(2014\)](#) shows set intersections (and their sizes) from a GSEA of four results against the MSigDB KEGG pathways. Set identity is indicated by the joined lines. Set size is indicated by the top bar chart. The bar chart on the left shows the total set size for each individual GSEA run. Results are filtered using a liberal FDR threshold of $FDR < 0.15$ for the RNA-Seq data and $FDR < 0.3$ for the meta-analysis data (see Methods).

List of Tables

1	This table details all studies included in the meta-analysis, and the number of probes available after establishing a final probe set. All subjects with a labelled condition other than typically developed (TD) were assigned to the autism spectrum disorder (ASD) group, except for the two Glatt et al. data sets where “Type-1 errors” were assigned to the TD group.	22
2	This table shows SVA-adjusted results for the sex-autism interaction for the RNA-Seq data (sorted by FDR-adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed without the adjustment of latent batch effects.	23
3	This table shows genes with the most sex-dependent dysregulation (and their chromosomal position), sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.	24
4	This table shows SVA-adjusted results for the main effects (i.e., of the ASD condition) for the RNA-Seq data (sorted by FDR-adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed without the adjustment of latent batch effects.	25
5	This table shows genes with the most sex-independent dysregulation (and their chromosomal position), sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.	26

Study ID	Probes (Intersect)	Females (TD)	Males (TD)	Females (ASD)	Males (ASD)
GSE6575	39561	3	9	8	36
GSE18123	19532	34	48	24	80
Glatt et al. Wave I	28424	28	40	23	88
Glatt et al. Wave II	28424	35	56	28	85
CHARGE	39561	15	75	15	103
Kong et al. 2013	19532	7	10	7	46

Table 1: This table details all studies included in the meta-analysis, and the number of probes available after establishing a final probe set. All subjects with a labelled condition other than typically developed (TD) were assigned to the autism spectrum disorder (ASD) group, except for the two Glatt et al. data sets where “Type-1 errors” were assigned to the TD group.

Transcript ID	Gene symbol	Transcript biotype	Log 2 FC	P-adj SVA	P-adj (no SVA)
ENST00000354042	SLC13A4	protein_coding	3.27	0.293	0.1136846
ENST00000379802	DSP	protein_coding	3.19	0.293	0.6534814
ENST00000262551	OGN	protein_coding	2.97	0.299	0.8169099
ENST00000371625	PTGDS	protein_coding	1.74	0.299	0.0329544
ENST00000223357	AEBP1	protein_coding	1.85	0.529	0.8713166

Table 2: This table shows SVA-adjusted results for the sex-autism interaction for the RNA-Seq data (sorted by FDR-adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed without the adjustment of latent batch effects.

	Location	Fisher	Fisher p-adj	Fisher (no SVA)	Fisher p-adj (noSVA)
TTF2	1p13.1	52.16404	0.0105053	28.88686	1.0000000
UTY	Yq11.221	50.59543	0.0198876	45.76688	0.1378710
KCNJ8	12p12.1	48.17048	0.0528841	38.16932	1.0000000
MAP1B	5q13.2	48.15632	0.0531822	47.94878	0.0578051
RAP2C	Xq26.2	47.70446	0.0637312	24.82099	1.0000000
PAFAH1B1	17p13.3	45.45517	0.1559409	17.84249	1.0000000
CRHR1	17q21.31	44.98624	0.1876599	43.46097	0.3416423
NCS1	9q34.11	44.79693	0.2021903	30.46521	1.0000000
CHST11	12q23.3	44.75342	0.2056750	21.19593	1.0000000
SH3BGR	21q22.2	44.61154	0.2174809	32.59585	1.0000000
BNC2	9p22.3-p22.2	44.40363	0.2360031	39.81245	1.0000000
RORA	15q22.2	43.52113	0.3335702	34.11125	1.0000000
HECA	6q24.1	43.22311	0.3747481	33.12178	1.0000000
FBRSL1	12q24.33	43.04625	0.4015007	35.53452	1.0000000
PAK3	Xq23	43.03339	0.4034965	43.20181	0.3780235
ZC3H7B	22q13.2	42.95711	0.4156536	35.03776	1.0000000
CAMK1D	10p13	42.80430	0.4411269	24.56439	1.0000000
TMED10	14q24.3	42.55614	0.4858196	17.45529	1.0000000

Table 3: This table shows genes with the most sex-dependent dysregulation (and their chromosomal position), sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.

Transcript ID	Gene symbol	Transcript biotype	Log 2 FC	P-adj (SVA)	P-adj (no SVA)
ENST00000390930	SNORD17	snoRNA	-2.98	1.54e-05	0.0000102
ENST00000410396	RNU2-2P	snRNA	-4.76	4.04e-05	0.0000000
ENST00000613119		snRNA	-3.23	9.18e-05	0.0000000
ENST00000258526	PLXNC1	protein_coding	0.48	0.00468	0.4273372
ENST00000393775	IGSF11	protein_coding	-1.18	0.00468	1.0000000
ENST00000459255	SCARNA10	snoRNA	-1.71	0.00468	0.0014803
ENST00000618786	RN7SL1	misc_RNA	-1.35	0.0124	0.0026454

Table 4: This table shows SVA-adjusted results for the main effects (i.e., of the ASD condition) for the RNA-Seq data (sorted by FDR-adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed without the adjustment of latent batch effects.

	Location	Fisher	Fisher p-adj	Fisher (no SVA)	Fisher p-adj (noSVA)
ARHGAP35	19q13.32	69.17663	0.0000083	59.97651	0.0004125
GIMAP8	7q36.1	58.39735	0.0008000	52.71485	0.0083436
UCHL3	13q22.2	55.85012	0.0023073	31.88589	1.0000000
SPART	13q13.3	53.75888	0.0054659	43.79029	0.2920570
HNRNPA3P1	10q11.21	53.16493	0.0069742	54.55326	0.0039291
ZNF721	4p16.3	53.02620	0.0073817	45.32102	0.1608751
MAGED2	Xp11.21	52.57098	0.0088931	31.43801	1.0000000
UBE2A	Xq24	52.15816	0.0105264	24.84369	1.0000000
KIF13B	8p12	51.80723	0.0121459	44.99172	0.1830060
POLR1A	2p11.2	51.21815	0.0154371	35.12970	1.0000000
PATL1	11q12.1	50.53892	0.0203385	37.55012	1.0000000
COX19	7p22.3	50.48910	0.0207524	51.68452	0.0126954
GNG5	1p22.3	50.42442	0.0213024	21.04799	1.0000000
HNRNPF	10q11.21	50.20526	0.0232786	52.19956	0.0102957
MUM1	19p13.3	50.09134	0.0243757	38.59229	1.0000000
MTERF4	2q37.3	49.77445	0.0277066	40.36576	1.0000000
KLF1	19p13.13	49.50019	0.0309497	35.07655	1.0000000
SART3	12q23.3	48.93549	0.0388576	51.89275	0.0116656
EIF3A	10q26.11	48.86929	0.0399046	48.66280	0.0429001
ESF1	20p12.1	48.82351	0.0406442	40.26756	1.0000000
TCEAL8	Xq22.1	48.76924	0.0415389	30.32699	1.0000000
RNF168	3q29	47.89156	0.0590766	40.39014	1.0000000
NUCB2	11p15.1	47.52251	0.0684739	46.57846	0.0981743
CCP110	16p12.3	47.21328	0.0774723	30.63996	1.0000000
ZNF569	19q13.12	47.18319	0.0784042	35.01402	1.0000000
CHP1	15q15.1	47.17381	0.0786939	46.71912	0.0928712
ZC3H7B	22q13.2	47.11959	0.0804103	31.75604	1.0000000
GNPDA1	5q31.3	46.86648	0.0889439	39.70348	1.0000000
ECI2	6p25.2	46.83204	0.0901676	54.27612	0.0044030
VCP	9p13.3	46.73363	0.0937667	33.68338	1.0000000
ARHGAP8	22q13.31	46.70772	0.0947338	50.13461	0.0237714
PGM1	1p31.3	46.58133	0.0996154	36.39139	1.0000000
ZNF286A	17p12	46.57586	0.0998268	31.41283	1.0000000

Table 5: This table shows genes with the most sex-independent dysregulation (and their chromosomal position), sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.